This study is an Ib/II phase clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a second-line treatment for unresectable locally advanced or metastatic pancreatic cancer.
Approximately 39-48 patients with unresectable locally advanced or metastatic pancreatic cancer, who have progressed on or are intolerant to first-line chemotherapy (albumin-bound paclitaxel + gemcitabine, AG regimen), will be enrolled. Treatment involves IBI363 combined with chemotherapy and continues until disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, or other protocol-specified reasons for discontinuation.
Signed written informed consent form (ICF)
Age 18-75 years
Histologically/cytologically confirmed, unresectable locally advanced or metastatic pancreatic cancer.
Disease progression or intolerance after first-line treatment with the AG regimen (gemcitabine + albumin-bound paclitaxel).
Previous histologically/cytologically confirmed components including adenosquamous carcinoma, medullary carcinoma, signet ring cell carcinoma, undifferentiated carcinoma, etc.
Prior treatment with PD-1/PD-L1 inhibitors or other immunotherapies.
Unresolved > Grade 1 toxicities related to prior anticancer therapy (except persistent Grade 2 alopecia, anemia, peripheral neuropathy, correctable electrolyte abnormalities, or well-controlled endocrine disorders with hormone replacement therapy).
History of hepatic encephalopathy, seizures, active/new/untreated CNS metastases, spinal compression, carcinomatous meningitis, or leptomeningeal metastases.
Single group
IBI363 + chemotherapy
DrugIBI363+chemotherapy
Adverse events (AEs)
Progression-Free Survival(PFS)
Objective Response Rate (ORR)
Disease control rate(DCR)
Overall Survival(OS)
Click on the lead sponsor to view all of their trials.
Ruijin Hospital
Lead sponsor
Innovent Biologics, Inc.
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
